B7-H3: a robust target for immunotherapy in prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

B7-H3: a robust target for immunotherapy in prostate cancer

Published:2024-07 Issue:7 Volume:10 Page:584-587
ISSN:2405-8033
Container-title:Trends in Cancer
language:en
Short-container-title:Trends in Cancer

Author:

Pulido Rafael^ORCID,López José I.^ORCID,Nunes-Xavier Caroline E.^ORCID

Publisher

Elsevier BV

Reference15 articles.

1. B7-H3 in cancer – beyond immune regulation;Flem-Karlsen;Trends Cancer,2018

2. Effect of tumor CD276 expression on infiltrating immune cells and clinicopathological features of prostate cancer;Liu;Prostate Cancer Prostatic Dis.,2023

3. CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer;Cheng;Nat. Commun.,2024

4. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases;Chavin;Clin. Cancer Res.,2009

5. Correlation of expression of major vault protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer;Nunes-Xavier;Pathol. Res. Pract.,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3